Skip to content

David Leahy

  • Professor
  • CEO
  • Molplex
  • 30PublicationsNumber of items in David's My Publications folder on Mendeley.
  • 3Followers

Recent publications

  • The panel of experts cloud pattern

    • Watson P
    • Hiden H
    • Woodman S
    • et al.
    Get full text
  • Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models

    • Leahy D
    Get full text

Professional experience



May 2008 - Present



January 2008 - Present



School of Chemistry and Pharmacy, University of East Anglia

July 1983 - May 2012(29 years)

Salts Grammar School

July 1972 - May 2012(40 years)


University of Cambridge, St John’s College

September 1972 - July 1976(4 years)


David Leahy has over 25 years experience in drug discovery and development working as scientist, manager and entrepreneur in innovative new technology, strategic change, and business start-up. He spent 15 years in Research with what is now AstraZeneca, developing innovative technologies alongside active drug discovery projects. At ICI/Zeneca he managed a major component of the drug discovery operation while also leading global strategic change initiatives aimed at improving productivity, particularly in the pre-clinical phase. He left Zeneca to found Cyprotex PLC a unique, commercially successful and globally recognised company with a niche position in the provision of laboratory information on multiple drug properties. Cyprotex is now the world's largest ADME Tox CRO. He led the company through start-up, flotation on the London Stock Exchange and on to commercial success as CEO and CSO. From 2007-2010, he held positions at Newcastle University in the Medical Faculty and as a “Professor of Practice in the Business School. He is now CEO and co-founder of "Molplex -Drug Discovery on Demand as well as Chairman of Inkspot -- "Workflow in the Cloud" businesses


Followers (3)

Following (3)